JAMA Oncology Author Interviews podcast

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC

0:00
15:06
Reculer de 15 secondes
Avancer de 15 secondes

D'autres épisodes de "JAMA Oncology Author Interviews"